Cellectar Biosciences Inc (CLRB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.42 (+0.83%), Market cap $0.02B, 52-week low–high $0.25 ~ $9.70.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and ne
Financial statements, price targets, institutional (13F) holdings and related news for Cellectar Biosciences Inc are updated in real time on BlackAll Trade.
Cellectar Biosciences Inc trades at $2.42 (+0.83%). Real-time quotes and charts are available on BlackAll Trade.
Cellectar Biosciences Inc has a market cap of about $0.02B.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's